SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To assess the incidence and risk factors of subretinal fibrosis and their impact on visual outcome in eyes with myopic CNV. Methods: Medical records of 72 eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy in a pro re nata regimen for myopic CNV that followed up for more than 1 year were retrospectively reviewed. The presence of subretinal fibrosis after anti-VEGF therapy was determined using both fundus photographs and optical coherence tomography. The incidence and risk factors of subretinal fibrosis were evaluated, and best-corrected visual acuity was compared between the eyes with and without subretinal fibrosis. Results: The incidences of subretinal fibrosis during the 1-year and whole follow-up period were 31.9% and 36.1%, respectively. Occurrence of subretinal fibrosis was associated with frequent CNV recurrence (P = 0.005) and poor baseline best-corrected visual acuity (P = 0.044) in a Cox proportional hazard model. Anatomically, the eyes with subretinal fibrosis showed more frequent progression of chorioretinal atrophy (95.7% vs. 71.4%, P = 0.027) and less frequent photoreceptor recovery (17.4% vs. 65.3%, P < 0.001) after anti-VEGF therapy. Occurrence of subretinal fibrosis was associated with poor vision at baseline (P = 0.011) and the final visit (P = 0.008) when compared with the findings in the nonoccurrence group. Conclusion: Development of subretinal fibrosis after anti-VEGF therapy was common in eyes with myopic CNV and was associated with CNV recurrence. Myopic eyes with subretinal fibrosis show progressive chorioretinal atrophy and poor visual outcome. Subretinal fibrosis occurs in approximately one third of eyes with myopic choroidal neovascularization (CNV) after antivascular endothelial growth factor therapy. Subretinal fibrosis leads to more frequent progression of chorioretinal atrophy, less frequent photoreceptor recovery, and poor visual outcomes. Choroidal neovascularization recurrence is associated with the development of subretinal fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Myopic CNV treated with anti-VEGF have been shown to have similar development of fibrotic scars and associated progressive chorioretinal atrophy with poor visual outcome.32”
From Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials (2018) · cites this paper as [32]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Enhanced Depth Imaging Spectral-Domain Optical Coherence Tomography
Spaide, R. F., Koizumi, H., & Pozonni, M. C. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.032 · Cited by 2,180
International Photographic Classification and Grading System for Myopic Maculopathy
Ohno-Matsui, K., Kawasaki, R., Jonas, J. B., Cheung, C. M. G., Saw, S.-M., Verhoeven, V. J. M., Klaver, C. C. W., Moriyama, M., Shinohara, K., Kawasaki, Y., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.022 · Cited by 866
Age-related Macular Degeneration Histopathologic Studies
Green, W. R., & Enger, C. (1993) · Ophthalmology · doi:10.1016/s0161-6420(93)31466-1 · Cited by 757
Grossniklaus, H. E., & Green, W. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.09.042 · Cited by 469
The posterior staphyloma of pathologic myopia.
Curtin, B. J. (1977) · Europe PMC (PubMed Central) · Cited by 428
Myopic Choroidal Neovascularization
Cheung, C. M. G., Arnold, J. J., Holz, F. G., Park, K. H., Lai, T. Y. Y., Larsen, M., Mitchell, P., Ohno-Matsui, K., Chen, S.-J., Wolf, S., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.04.028 · Cited by 416
Self-citationNatural History of Choroidal Neovascularization in Degenerative Myopia
Avila, M. P., Weiter, J. J., Jalkh, A. E., Trempe, C. L., Pruett, R. C., & Schepens, C. L. (1984) · Ophthalmology · doi:10.1016/s0161-6420(84)34116-1 · Cited by 402
Etiology of Choroidal Neovascularization in Young Patients
Cohen, S. Y., Laroche, A., Leguen, Y., Soubrane, G., & Coscas, G. J. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30515-0 · Cited by 392
Cited by
Daniel, E., Pan, W., Ying, G.-S., Kim, B. J., Grunwald, J. E., Ferris, F. L., Jaffe, G. J., Toth, C. A., Martin, D. F., Fine, S. L., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.004 · Cited by 119
“Myopic CNV treated with anti-VEGF has been shown to have similar development of fibrotic scars and associated progressive chorioretinal atrophy with poor visual outcome.(32) However,”
Critical roles of miR-21 in promotions angiogenesis: friend or foe?
Saadh, M. J., Jasim, N. Y., Ahmed, M. H., Ballal, S., Kumar, A., Atteri, S., Vashishth, R., Rizaev, J. A., Alhili, A., Jawad, M. J., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01600-7 · Cited by 29
Hu, X., Zhao, X., Li, S., Sun, L., Wen, X., Wang, Z., Zhang, A., Zhang, J., & Ding, X. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315763 · Cited by 27
Bo, Q., Shen, M., Xiao, M., Liang, J., Zhai, Y., Zhu, H., Jiang, M., Wang, F., Luo, X., & Sun, X. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0112 · Cited by 24
Bae, K. W., Kim, D., Kim, B. H., Oh, B., Lee, E. K., Yoon, C. K., & Park, U. C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273613 · Cited by 20
Metadata
- Authors
- Ahn, S. J., Park, K. H., & Woo, S. J.
- Affiliations
- Seoul National University Bundang Hospital (KR)
- Venue
- Retina
- Published
- 2016-11
- Volume
- 36
- Issue
- 11
- Pages
- 2140-2149
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2342491423
- Cited by
- 25
- References
- 32
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 3
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- subretinal fibrosis, myopic choroidal neovascularization, anti-VEGF therapy, pro re nata regimen, chorioretinal atrophy, photoreceptor recovery, best-corrected visual acuity, risk factors, visual outcome
- MeSH terms
- Bevacizumab, Ranibizumab, Adult, Aged, Female, Fibrosis, Humans, Male, Middle Aged, Photography, Retina, Retrospective Studies, Risk Factors, Visual Acuity, Incidence, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Myopia, Degenerative
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. https://app.cochat.ai/papers/10.1097/iae.0000000000001043
- The paper
- Ahn, S. J., Park, K. H., & Woo, S. J. (2016). SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina. https://doi.org/10.1097/iae.0000000000001043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.